Bottom line
NICE recommends teplizumab for delaying the onset of stage 3 type 1 diabetes in people aged 8 years and over with stage 2 disease. The important verb is delaying: this is not a cure, it does not prevent all progression and it is not a treatment for type 2 diabetes.
Why this is a genuine shift
Type 1 diabetes care has historically focused on replacing insulin after symptomatic disease develops. Teplizumab is an anti-CD3 monoclonal antibody aimed at modifying the autoimmune process before stage 3 disease, moving part of care upstream into identification and monitoring of stage 2 disease.
What the pivotal evidence showed
The pivotal randomized placebo-controlled study enrolled 76 at-risk relatives with stage 2 type 1 diabetes. Teplizumab delayed progression to clinical stage 3 disease compared with placebo. The sample was small and selected, so eligibility, longer-term effect and implementation remain important parts of interpreting the result.
What remains practical rather than headline-level
- People must first be identified as having stage 2 disease; this is not the same as population-wide treatment.
- The therapy requires a defined infusion course and clinical monitoring.
- NICE recommendation, marketing authorisation, local pathway readiness and individual eligibility are related but distinct questions.
- Use NICE guidance, the product information and specialist pathways for clinical decisions—not this summary.
Evidence snapshot
- Population
- People aged 8+ with stage 2 type 1 diabetes; pivotal trial enrolled 76 at-risk relatives
- Intervention
- Teplizumab, an anti-CD3 monoclonal antibody
- Comparator
- Placebo in the pivotal randomized study
- Primary question
- Time from stage 2 to clinical stage 3 type 1 diabetes
- UK status
- Recommended by NICE in TA1176 for the specified population
- Key uncertainty
- Long-term effect, pathway delivery and generalisability beyond the selected trial population
Evidence, interpreted
Quick analysis
- Study design
- Phase 2, randomised, double-blind, placebo-controlled trial; peer-reviewed publication.
- Population
- 76 relatives of people with type 1 diabetes who were aged 8 years or older and met the trial definition of stage 2 disease.
- Principal finding
- A single 14-day teplizumab course delayed progression to stage 3 type 1 diabetes compared with placebo in this selected high-risk group.
- Limitations
- The trial was small and enrolled a selected group of at-risk relatives rather than a population-screened cohort.
- It established delay rather than prevention or cure, and the original comparison could not answer every long-term safety, durability or implementation question.
- Real-world benefit depends on identifying stage 2 disease and delivering specialist monitoring and infusions.
- Residual uncertainty
- The durability of benefit, repeat-treatment role, broader generalisability and practical UK screening pathway remain important questions.
- Conflicts or funding
- The pivotal study was led through NIH-funded TrialNet with additional foundation support; MacroGenics donated the study medicines and funded additional site monitoring. Author disclosures in the paper remain relevant.
- UK-practice impact
- ChangedNICE TA1176 recommends teplizumab for the specified population, but eligibility, identification and local pathway readiness still determine access.
Original sources
- TA1176: Teplizumab for delaying stage 3 type 1 diabetesNICE ↗
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesNew England Journal of Medicine ↗
- NCT01030861 trial recordClinicalTrials.gov ↗
Sources last checked 10 August 2026. If an official source and this summary differ, use the official source.